Core Viewpoint - Yiling Pharmaceutical's Lianhua Qingke Pian has been awarded as a top brand for household medicines (cough relief and phlegm removal) at the "2024-2025 Annual Household Medicine Top Brand" award ceremony, highlighting its effectiveness in treating respiratory diseases and improving quality of life [1][2] Group 1: Product Efficacy - Lianhua Qingke Pian is guided by traditional Chinese medicine theory and has multiple functions including clearing the lungs, resolving phlegm, and relieving cough, making it widely applicable for various respiratory diseases such as colds, flu, pneumonia, and acute exacerbations of chronic obstructive pulmonary disease [1] - Clinical studies have confirmed that Lianhua Qingke Pian has significant antiviral and antibacterial effects, effectively controlling airway inflammation, reducing cough frequency, shortening cough duration, and improving cough resolution rates [1] - The product also reduces phlegm production, lowers phlegm viscosity, promotes phlegm expulsion, protects airway mucosa, alleviates airway spasms, and improves airway resistance, thereby reducing recurrent airway inflammation and lung damage [1] Group 2: Clinical Research and Recognition - A randomized, double-blind, placebo-controlled, multi-center study involving 480 patients demonstrated that Lianhua Qingke Pian has a rapid cough relief and phlegm resolution effect, with a total clinical efficacy rate of 92.39% and no adverse reactions reported during the study [2] - Due to its proven clinical efficacy and scientific support, Lianhua Qingke Pian has been included over 50 times in national and provincial guidelines, consensus, and treatment plans for respiratory infections, indicating its recognized role in treating cough and phlegm symptoms [2] - The "Household Medicine Top Brand" event has been held for nine years, serving as a trusted reference for families in China, enhancing health management and guiding rational medication use [2]

Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]

Core Viewpoint - Yiling Pharmaceutical's stock price has shown a year-to-date increase of 24.19%, but has recently experienced a decline of 4.69% over the past five trading days, indicating volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported a revenue of 5.868 billion yuan, representing a year-on-year decrease of 7.82%. However, the net profit attributable to shareholders increased by 80.33% to 1 billion yuan [2]. - The company has cumulatively distributed 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Yiling Pharmaceutical was 152,700, a decrease of 10.22% from the previous period. The average number of circulating shares per shareholder increased by 11.38% to 9,013 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 25.704 million shares, an increase of 8.112 million shares compared to the previous period. Meanwhile, the Southern CSI 500 ETF reduced its holdings by 256,900 shares [3]. Market Activity - Yiling Pharmaceutical's stock experienced a trading volume of 347 million yuan with a turnover rate of 1.28% as of November 18. The total market capitalization stood at 32.595 billion yuan [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 64.0503 million yuan on January 6, accounting for 14.28% of total trading volume [1].

Core Viewpoint - Yiling Pharmaceutical's subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material, Memantine Hydrochloride, which is used to treat moderate to severe Alzheimer's disease [1] Group 1 - The approved product, Memantine Hydrochloride, is a voltage-dependent, moderately affinity non-competitive NMDA receptor antagonist [1]

Core Viewpoint - The market experienced fluctuations last week, but several component stocks in the brand index rose against the trend, indicating potential resilience in certain sectors and a positive outlook for the A-share market as companies may enter a performance release phase [1][4]. Market Performance - The market saw a decline with the Shanghai Composite Index down 0.18%, Shenzhen Component Index down 1.40%, and ChiNext Index down 3.01%. The brand index fell 0.11% to 2019.62 points [2]. - Notable gainers included Jinjiang Hotels, which rose 13.13%, Yiling Pharmaceutical up 12.45%, and China Duty Free up 11.76%. Other stocks like Xintai, Luzhou Laojiao, and several others also saw increases of over 5% [2]. Year-to-Date Performance - Since the beginning of the second half, stocks like Zhongji Xuchuang have surged 217.63%, followed by Sunshine Power at 174.76%, and Yiwei Lithium Energy at 80.90%. Other companies also reported significant gains, with many stocks increasing over 60% [3]. Future Outlook - Analysts from Xingshi Investment suggest that the domestic economic momentum is recovering, and companies are likely to enter a performance release phase, shifting the market's main driving force from valuation to performance [4]. - Huatai Bairui Fund noted that economic data from October shows continued production resilience, with expectations for stable domestic fundamentals and liquidity in the fourth quarter. There is potential for improved corporate performance driven by domestic policy [4].

Core Insights - The "2025 China Health Industry Development and Rehabilitation Service Conference" will focus on technological innovation in the health sector, aligning with the "14th Five-Year Plan" to enhance self-reliance in health technology [2][5] - The health industry in China has seen significant growth, expanding from 7.4 trillion yuan to 12.3 trillion yuan over five years, with advancements in AI medical applications and CAR-T therapies [2][5] Academic Leadership - The conference will feature prominent academic figures, including academician Fan Daiming, who will discuss integrated medicine and its relevance to the "14th Five-Year Plan" [5][6] - Fan's presentation will focus on breakthroughs in the diagnosis and treatment of digestive diseases, emphasizing the importance of integrated prevention and management [5][6] Industry Practices - Over 50 leading companies from various sectors of the health industry will participate, covering innovative drug development, medical devices, healthcare services, health management, and digital health [8][9] - The conference will include roundtable discussions addressing key industry issues, such as investment opportunities in innovative drugs and the commercialization of brain-computer interfaces [9][10] Innovation and Collaboration - The event will facilitate direct interactions between experts and companies to address technological challenges and foster collaboration [6][12] - A showcase area will feature over 20 representative companies displaying their latest technologies and core products, enhancing visibility for industry innovations [12][13] Authoritative Results and Reports - The conference will release significant reports, including the "2025 China Health Industry White Paper" and the "Hua Xia ESG Dandelion 50-30 Index 2025 Annual Report," providing valuable insights and benchmarks for the industry [13][15] - The ESG report will evaluate 50 A-share companies and 30 H-share growth companies based on environmental, social, and governance criteria, supporting sustainable development in the health sector [13][15] Future Directions - The conference aims to create a continuous service platform for the health industry, ensuring that innovative practices and authoritative findings are effectively implemented [16][17] - The event will gather experts, industry leaders, and investment representatives to collaboratively shape the future of the health industry in China [16][17]

Core Insights - The avian influenza concept sector saw an increase of 1.21%, ranking 10th among concept sectors, with 16 stocks rising, including Zhongsheng Pharmaceutical which hit the daily limit, and Hualan Vaccine, Kangyuan Pharmaceutical, and Yiling Pharmaceutical showing notable gains of 7.22%, 4.53%, and 3.14% respectively [1][2] Group 1: Stock Performance - Zhongsheng Pharmaceutical led the sector with a net inflow of 7.32 billion yuan, while Kangyuan Pharmaceutical, Yiling Pharmaceutical, and Hualan Vaccine also experienced significant net inflows of 3274.76 million yuan, 3130.43 million yuan, and 2904.55 million yuan respectively [2][3] - The top gainers in the avian influenza concept included Zhongsheng Pharmaceutical with a daily increase of 9.98%, followed by Hualan Vaccine at 7.22%, and Kangyuan Pharmaceutical at 4.53% [3][4] Group 2: Market Trends - The avian influenza concept sector attracted a net inflow of 6.66 billion yuan today, with 10 stocks receiving net inflows, and 6 stocks exceeding 10 million yuan in net inflow [2] - The net inflow ratios for leading stocks were 36.05% for Zhongsheng Pharmaceutical, 8.22% for Dongfang Bio, and 7.21% for Rhine Bio, indicating strong investor interest in these companies [3][4]

Core Insights - The traditional Chinese medicine sector experienced a slight increase of 0.52% on November 14, with Jia Ying Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Jia Ying Pharmaceutical (002198) closed at 7.66, up 10.06% with a trading volume of 275,500 shares and a transaction value of 203 million yuan [1] - Zhongsheng Pharmaceutical (002317) closed at 26.00, up 9.98% with a trading volume of 791,200 shares and a transaction value of 2.03 billion yuan [1] - Te Yi Pharmaceutical (002728) closed at 15.21, up 9.98% with a trading volume of 1,662,000 shares and a transaction value of 2.44 billion yuan [1] - Other notable performers include Fangsheng Pharmaceutical (603998) with a 4.92% increase and Kangyuan Pharmaceutical (600557) with a 4.53% increase [1] Capital Flow - The traditional Chinese medicine sector saw a net inflow of 541 million yuan from institutional investors, while retail investors experienced a net outflow of 17.84 million yuan [2] - Major stocks like Zhongsheng Pharmaceutical and Te Yi Pharmaceutical had significant net inflows from institutional investors, indicating strong interest [3] - Conversely, retail investors showed a tendency to withdraw from several stocks, including Jia Ying Pharmaceutical and Kangyuan Pharmaceutical, reflecting a cautious sentiment [3]

Group 1 - Yiling Pharmaceutical's stock increased by 5.29%, reaching 21.49 CNY per share, with a trading volume of 1.012 billion CNY and a turnover rate of 3.50%, resulting in a total market capitalization of 35.903 billion CNY [1] - The company, established on August 28, 2001, and listed on July 28, 2011, is located in the High-tech Industrial Development Zone of Shijiazhuang, Hebei Province, focusing on the research, production, and sales of traditional Chinese medicine [1] - The revenue composition of Yiling Pharmaceutical includes cardiovascular products at 48.60%, respiratory system products at 22.80%, other products at 22.52%, and patented products at 6.08% [1] Group 2 - Huatai-PineBridge Fund has one fund heavily invested in Yiling Pharmaceutical, with a reduction of 11,000 shares in the third quarter, holding a total of 150,200 shares, which accounts for 3.25% of the fund's net value, ranking as the eighth largest holding [2] - The fund, established on July 26, 2022, has a current size of 73.3687 million CNY, with a year-to-date return of 3.17%, ranking 4132 out of 4216 in its category, and a one-year loss of 3.9%, ranking 3883 out of 3955 [2] - The fund manager, Chen Kehan, has been in position for 114 days, overseeing total assets of 2.226 billion CNY, with the best return during the tenure at 2.93% and the worst at -7.96% [2]

Group 1 - The core viewpoint indicates a strong performance in the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index rising by 1.22% and individual stocks like Zhongsheng Pharmaceutical increasing by 9.98% [1] - The TCM ETF has shown a consistent upward trend, achieving an 8-day consecutive rise, with the latest price reported at 1.06 yuan [1] - The National Health Commission has projected a peak in influenza cases in China during mid-December to early January, which may positively impact the TCM market [1] Group 2 - CITIC Securities anticipates that the collection of traditional Chinese medicine will continue to expand, leading to increased brand concentration in the outpatient market [1] - The TCM industry is expected to reach a healthy inventory level by Q2 2025, following a period of destocking and sales efforts [1] - Continuous growth in R&D investment by TCM companies is highlighted as a key driver for future development, with a focus on innovative TCM contributing to stable growth [1]